Literature DB >> 10566897

Gene expression along the cerebral-spinal axis after regional gene delivery.

C Meuli-Simmen1, Y Liu, T T Yeo, D Liggitt, G Tu, T Yang, M Meuli, S Knauer, T D Heath, F M Longo, R J Debs.   

Abstract

We demonstrate here that intracerebroventricular or spinal cord (intrathecal) injection of either plasmid DNA alone or cationic liposome: DNA complexes (CLDCs) produces significant levels of expression of both reporter genes and biologically relevant genes in nonparenchymal cells lining both the brain and the spinal cord. Gene expression was identified both within the spinal cord and the brain after intracerebroventricular or intrathecal injection of either CLDCs or plasmid DNA alone. Intracerebroventricular or intrathecal injection of CLDCs containing the beta-galactosidase (beta-Gal) gene produced patchy, widely scattered areas of beta-Gal expression. The chloramphenicol acetyltransferase (CAT) reporter gene product reached peak levels between 24 hr and 1 week postinjection, and was still present at significant levels 3 weeks after a single intracerebroventricular or intrathecal injection. Intrathecal injection of the human granulocyte colony-stimulating factor (G-CSF) gene produced high levels of hG-CSF activity in both the spinal cord and the brain. Intracerebroventricular injection of CLDCs containing the murine nerve growth factor (NGF) gene increased mNGF levels in the hippocampus, a target region for cholinergic neurons in the medial septum, and increased cholinergic neurotransmitter synthetic enzyme choline acetyltransferase (ChAT) activity within the brain, a well-characterized effect of both purified and recombinant NGF protein. These findings indicate that intracerebroventricular or intrathecal injection of CLDCs can produce significant levels of expression of biologically and therapeutically relevant genes within the CNS. Efficient gene transfer into the CNS will facilitate the evaluation of gene function and regulation within the brain and spinal cord. We attempted to transfer and express genes within the brain and spinal cord by direct CNS injection of either DNA alone or CLDCs into the intraventricular and subarachnoid compartments. We show that intracerebroventricular or spinal cord (intrathecal) injection of either plasmid DNA alone or CLDCs produces significant levels of expression of both reporter genes and biologically relevant genes in nonparenchymal cells lining both the brain and the spinal cord. Intrathecal injection of the hG-CSF gene produced high levels of hG-CSF activity in both the spinal cord and the brain. Intracerebroventricular injection of CLDCs containing the murine NGF gene increased mNGF levels in the hippocampus, and increased cholinergic neurotransmitter synthetic enzyme ChAT activity within the brain. Locoregional diffusion of gene products expressed by transfected meningeal lining cells into brain and spinal cord parenchyma could potentially target secreted proteins within brain and spinal cord regions relevant to neuropathological states while limiting peripheral side effects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10566897     DOI: 10.1089/10430349950016735

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  14 in total

Review 1.  Central nervous system delivery of large molecules: challenges and new frontiers for intrathecally administered therapeutics.

Authors:  Ryan G Soderquist; Melissa J Mahoney
Journal:  Expert Opin Drug Deliv       Date:  2010-03       Impact factor: 6.648

Review 2.  Physiology of the intrathecal bolus: the leptomeningeal route for macromolecule and particle delivery to CNS.

Authors:  Mikhail I Papisov; Vasily V Belov; Kimberley S Gannon
Journal:  Mol Pharm       Date:  2013-02-12       Impact factor: 4.939

Review 3.  Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations.

Authors:  R G Thorne; W H Frey
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 4.  The therapeutic potential of interleukin-10 in neuroimmune diseases.

Authors:  A J Kwilasz; P M Grace; P Serbedzija; S F Maier; L R Watkins
Journal:  Neuropharmacology       Date:  2014-11-04       Impact factor: 5.250

5.  Immunogenicity of intrathecal plasmid gene delivery: cytokine release and effects on transgene expression.

Authors:  Travis S Hughes; Stephen J Langer; Salla I Virtanen; Raymond A Chavez; Linda R Watkins; Erin D Milligan; Leslie A Leinwand
Journal:  J Gene Med       Date:  2009-09       Impact factor: 4.565

6.  Intrathecal polymer-based interleukin-10 gene delivery for neuropathic pain.

Authors:  Erin D Milligan; Ryan G Soderquist; Stephanie M Malone; John H Mahoney; Travis S Hughes; Stephen J Langer; Evan M Sloane; Steven F Maier; Leslie A Leinwand; Linda R Watkins; Melissa J Mahoney
Journal:  Neuron Glia Biol       Date:  2006-11

7.  Intrathecal injection of naked plasmid DNA provides long-term expression of secreted proteins.

Authors:  Travis S Hughes; Stephen J Langer; Kirk W Johnson; Raymond A Chavez; Linda R Watkins; Erin D Milligan; Leslie A Leinwand
Journal:  Mol Ther       Date:  2008-10-21       Impact factor: 11.454

8.  Neuroprotective effect of A20 on TNF-induced postischemic apoptosis.

Authors:  Luyang Yu; Hongsheng Miao; Yanan Hou; Bao Zhang; Lihe Guo
Journal:  Neurochem Res       Date:  2006-01       Impact factor: 3.996

9.  Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells.

Authors:  Arvind Kumar; Tryambak D Singh; Santosh K Singh; Satya Prakash
Journal:  Biologics       Date:  2009-07-13

10.  Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery.

Authors:  Chris Towne; Marie Pertin; Ahmed T Beggah; Patrick Aebischer; Isabelle Decosterd
Journal:  Mol Pain       Date:  2009-09-08       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.